FDA will require device makers to tell patients directly when implants fail
S. 3421 — Medical Device Recall Improvement Act of 2025 · Filed by Richard Durbin (D-IL) · Introduced Dec 10, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires medical device manufacturers to notify patients directly when their implanted or life-sustaining devices are recalled, using a standardized electronic format. The FDA must establish the notification system within 2 years, review manufacturer notifications within 2–3 business days, and maintain a public database of all device recalls. Manufacturers who fail to notify patients or use the required format face penalties under federal law.
Why we flagged it
The bill's core function is to mandate direct patient notification of device recalls and establish transparent, standardized electronic reporting. It is a public-health transparency measure, not a deregulatory or industry-favoring provision.
What the text implies
- Manufacturers may face operational costs to build/integrate electronic notification systems, potentially passed to healthcare systems or patients through device pricing.
- The 2–3 business day FDA review window creates a tight timeline; delays could expose patients to risk or create liability disputes over notification timing.
- Public database of recalls may increase litigation risk for manufacturers by making failure-to-warn claims easier to document and litigate.
- Patient notification requirement applies only to class I/II recalls of implanted, life-sustaining, or pediatric-use devices—narrower scope may leave other high-risk devices without direct patient notice.
Who it affects
Patients with implanted or life-sustaining devices gain direct knowledge of safety risks and corrective actions, enabling them to seek medical attention or device replacement. The public database increases transparency and accountability. The burden on manufacturers is procedural compliance, not substantive deregulation or cost-shifting to consumers.
Who stands to gain
- healthcare IT vendors (electronic notification system development)
- medical device manufacturers (compliance consulting, system integration)
Named in the bill
FDA (Food and Drug Administration), Section 518B (new electronic notification requirement), Section 518C (patient notification requirement), Section 519 (existing recall notification authority), Section 301 (prohibited acts), Class I, II, III medical devices, Device user facilities, Manufacturers and importers
Where it stands
- Dec 10, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Dec 10, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S8625)”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the full bill text on Jun 8, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“FDA will require device makers to tell patients directly when implants fail” QuorumCivic. https://share.quorumcivic.app/bill/119/s3421 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.